Twenty-one patients, ri with normal pulmonary artery pressures and Io with pulmonary hypertension, had haemodynamic measurements performed before and during dopamine infusion while undergoing cardiac catheterization, in order to evaluate the circulatory effects of dopamine in pulmonary hypertension. In both groups on average, heart rate, pulmonary artery mean pressure, aortic mean pressure, and cardiac index increased sigmficantly, while systemic vascular resistance fell significantly during dopamine adninistration. In neithergroup did the average pulmonary vascular resistance or right ventricular end-diastolicpressure change sigmficantly. We conclude that dopamine is a safe and potentially useful drug for the treatment of reduced cardiac output, even in patients with pulmonary hypertension.
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Dopamine is a naturally occurring catecholamine which is the direct biochemical precursor in the synthesis of norepinephrine (Blaschko, 1957) . Its use has been advocated for the treatment of shock (Goldberg, 1972; Harrison et al., I969; Loeb et al., 197i) , and in the low output syndrome associated with cardiac surgery (MacCannell et al., I966) . These, and other studies summarized by Rosenblum and Frieden (1972) and Goldberg (1972) have demonstrated that dopamine is a potent stimulator of myocardial contractile state which appears to cause a smaller increase in heart rate for a given increase in contractility than other adrenergic agents. In the systemic circulation, dopamine acts primarily as an a-adrenergic stimulator, but this is countered by direct coeliac, mesenteric, and renal artery dilatation resulting in increased renal blood flow and urine output (Talley et indicated that dopamine caused a pressor reponse in the pulmonary circulation which suggested that in patients with pulmonary hypertension, dopamine might prove detrimental. This might occur if dopamine administration resulted in an increase in pulmonary arteriolar constriction when pulmonary pressures were already increased by direct vascular changes, hypoxia, or arterial hypercarbia. Thus, dopamine administration in patients with an already raised pulmonary resistance might result in acute right heart failure and even more severe pulmonary hypertension.
In order to test this hypothesis, acute studies were carried out in the cardiac catheterization laboratory on a group of patients with normal pulmonary arterial pressures and a group of patients with raised pulmonary artery pressures. Dopamine was administered to both groups and their circulatory responses compared.
Subjects and methods
Twenty-one patients undergoing routine diagnostic cardiac catheterization were studied, II with normal resting pulmonary artery pressure (pulmonary artery mean pressure<20 mmHg (2.7 kPa)) and io with pulmonary hypertension (pulmonary artery pressure .30 mmHg (4.o kPa)). All had disease affecting left ventricular function, either coronary artery disease or cardiomyopathy, and none had primury valvular heart disease or primary pulmonary hypertension. Dopamine administration, in the moderate dose range used, again demonstrated its effectiveness in increasing cardiac index and reducing calculated systemic vascular resistance, presumably through its vasodilatation of the splanchnic vascular bed (Rosenblum, Tai, and Lawson, I972) . This increase in cardiac index occurred in both patient groups, though the group with pulmonary hypertension had a greater accompanying increase in heart rate, and therefore in myocardial oxygen demands.
In both groups, dopamine infusion resulted in significant increases in pulmonary artery pressure. However, in neither group did the mean calculated pulmonary vascular resistance increase though it did in 4 patients with pulmonary hypertension (Fig.) . Therefore, the rise in puLlmonary artery pressure after dopamine administration generally was not the result of an increase in pulmonary vascular constriction, but rather was secondary to increased right heart output. This was true both for patients with normal pulmonary artery pressure and for patients with raised pulmonary artery pressure. Significant decreases in systemic vascular resistance occurred in both groups of patients, and, though slight decreases in pulmonary vascular resistance occurred in individual subjects, the mean change was not statistically significant in either group. There was no significant increase in right ventricular end-diastolic pressure suggestive of right heart 
